Share on Facebook Share on Twitter

Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
CDC ACIP slides 1/27/2021
#1
There is an interesting set of slides from an ACIP working group dated 1/27/2021.

Efficacy estimate for the dual standard-dose regimen of the AZ vaccine is 62% (41-75%).  Pooled with the low-dose/standard-dose regimen, the overall estimate of efficacy is 70.4% (55-81%).  32,000 people will be in US Phase III trials (2 equal doses), and that will be what is used for judging it.

Regarding different strains:
Quote:Following vaccination, study participant sera (n=8–20) tested in neutralization assays:
  • Pfizer BioNTech COVID-19 vaccine: 
    • Several studies have demonstrated equivalent neutralizing titers against a panel of 19 individual  SARS-CoV-2 spike variants1  and N501Y (variant)2 compared to wildtype virus
    • Reductions to neutralizing titers have been noted against the B.1.1.7 (UK) variant (all mutations):
      • 1.3-fold average reduction3
      • 3.9-fold median reduction4
    • One study with modest reduction (<3-fold) for some with neutralization against certain SARS-CoV-2 spike mutations from B.1.351 (South African) and P.1 (Brazil) variants: E484K and K417N:E484K:N501Y5
  • Moderna COVID-19 Vaccine:
    • One study with modest reduction (<3-fold) for some with neutralization against certain SARS-CoV-2 spike mutations from B.1.351 (South African) and P.1 (Brazil) variants: E484K and K417N:E484K:N501Y5
    • Another study with no significant impact on neutralizing titers against B.1.1.7 (UK) variant, but 6-fold reduction for B.1.351 (South African) variant

Moderna has announced they are developing a vaccine against B.1.351 (South African) variant

Quote:Efficacy after dose 1 Phase III data
  • Pfizer-BioNTechCOVID-19 vaccine
    • Most (98%) recipients received 2 doses of the Pfizer-BioNTech vaccine
    • Efficacy of 52.4% (29.5–68.4%) noted between dose 1 and dose 2
    • Additional data in UK press statement (not included in submission to FDA or CDC):
      • Cases from day 15-day 21: VE of 89% (52-97%)
      • Follow-up only until day 21
  • Moderna COVID-19 vaccine
    • Most (97%) recipients received 2 doses of the Moderna vaccine
    • Efficacy of 69.5% (43.5–84.5%) noted between dose 1 and dose 2
    • Additional data from Moderna Phase III trial: 
      • Non-randomized sample of persons who only received 1 dose: VE of 92% (66–98%), 
      • Median follow-up only 28 days
Reply


Forum Jump:


Users browsing this thread: 1 Guest(s)